Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15396540 | 0.89 | SMN1; SMN2 (0.70) | SMN1; SMN2ADORA2BRXFP1NPSR1MAPK1 | |
| SCHEMBL25293608 | 0.89 | SMN1; SMN2 (0.70) | SMN1; SMN2ADORA2BRXFP1NPSR1MAPK1 | |
| SCHEMBL12260494 | 0.84 | SMN1; SMN2 (0.76) | SMN1; SMN2ADORA2BRXFP1NPSR1MAPK1 | |
| SCHEMBL10850696 | 0.82 | SMN1; SMN2 (0.82) | SMN1; SMN2ADORA2BRXFP1NPSR1MAPK1 | |
| SCHEMBL17635429 | 0.82 | SMN1; SMN2 (0.62) | SMN1; SMN2ADORA2BRXFP1NPSR1MAPK1 | |
| SCHEMBL28651010 | 0.82 | SMN1; SMN2 (0.65) | SMN1; SMN2ADORA2BRXFP1NPSR1MAPK1 | |
| SCHEMBL10178027 | 0.81 | SMN1; SMN2 (1.00) | SMN1; SMN2ADORA2BRXFP1NPSR1MAPK1 | |
| SCHEMBL10178054 | 0.80 | SMN1; SMN2 (0.63) | SMN1; SMN2ADORA2BRXFP1NPSR1MAPK1 | |
| SCHEMBL10500882 | 0.80 | ADORA2B (0.83) | SMN1; SMN2ADORA2BRXFP1MAPK1MAPT | |
| SCHEMBL20715459 | 0.80 | RXFP1 (0.58) | SMN1; SMN2ADORA2BRXFP1NPSR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296691-B2 | Inhibitors of p75 receptor and their uses | HORACIO URI SARAGOVI (CA) | 2016-03-29 | — | — | US | disclosed |
| US-9296691-B2 | Inhibitors of p75 receptor and their uses | HORACIO URI SARAGOVI (CA) | 2016-03-29 | — | — | US | disclosed |
| US-20130310404-A1 | INHIBITORS OF P75 RECEPTOR AND THEIR USES | SARAGOVI, HORACIO URI (CA) | 2013-11-21 | — | — | US | disclosed |
| WO-2012048417-A1 | INHIBITORS OF P75 RECEPTOR AND THEIR USES | SARAGOVI HORACIO URI (CA) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310404-A1 | INHIBITORS OF P75 RECEPTOR AND THEIR USES | NTRK2, NGFR, NGF | SMN1; SMN2 32/4885ADORA2B 2163/4885RXFP1 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.